Hepatotoxicity with KRASG12C Inhibitors in NSCLC
December 21st 2023Dr Narjust Florez discusses the hepatoxicity associated with KRAS G12C inhibitors, noting both adagrasib and sotorasib pose liver damage risks, but real-world data suggests adagrasib may have a lower risk; she emphases the importance of considering other causes of hepatoxicity before attributing it solely to these therapies.
2-Minute Drill: The Biggest Surprise From the 2023 ASH Annual Meeting
December 19th 2023Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss highlights of the conference in a game show–style production.
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC
December 19th 2023The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.